Phase 3 biotech developing oncolytic viral immunotherapies for solid tumors.
Industry: Health Care
Latest Trade: $2.46 0.00 (0.0%)
First Day Return: +2.5%
Return from IPO: -59.0%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 06/24/2022 |
Offer Price | $6.00 |
Price Range $6.00 - $7.00 | |
Offer Shares (mm) | 2.5 |
Deal Size ($mm) | $15 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 01/25/2023 |
Offer Price | $6.00 |
Price Range $6.00 - $7.00 | |
Offer Shares (mm) | 2.5 |
Deal Size ($mm) | $15 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
The Benchmark Company |
Brookline Capital Markets |
Company Data | |
---|---|
Headquarters | Westlake Village, CA, United States |
Founded | 2001 |
Employees at IPO | 15 |
Website www.genelux.com |